FDA Awards Orphan Drug Designation to Losmapimod for Treatment of FSHD

Article

Although there are no approved therapies for FSHD, researchers at Fulcrum Therapeutics discovered that inhibition of p38α/β reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD.

Fulcrum Therapeutics has received orphan drug designation for losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor for the treatment of facioscapulohumeral muscular dystrophy (FSHD).1

FSHD is a rare disease characterized by muscle weakness and atrophy. Symptoms typically appear in early adulthood, but can begin in infancy or later in adulthood. Progression of the disease is typically slow, and it is estimated to effect between 4 and 10 per 100,000 people. It is caused by abnormal expression of the DUX4 gene.2

In the reduction of DUX4 expression, p38α/β inhibitors such as losmapimod play an important role. Although there are no approved therapies for FSHD, researchers at Fulcrum Therapeutics discovered that inhibition of p38α/β reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD.

The company announced preliminary results from a Phase 1 clinical trial in October 2019, which found that losmapimod was generally well-tolerated and achieved dose-dependent concentrations in plasma and muscle believed to be adequate for efficacy based on preclinical pharmacology studies.

The drug was evaluated in over 3500 subjects in clinical trials across multiple other indications. No safety signals were attributed to losmapimod in any of the trials, and Fulcrum is currently conducted Phase 2 trials investigating the safety, tolerability, and efficacy of losmapimod to treat the root cause of FSHD.

REFERENCES

  • Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio [news release]. Cambridge, MA; Jan 29, 2020. GlobeNewswire. https://www.globenewswire.com/news-release/2020/01/29/1976751/0/en/Fulcrum-Therapeutics-Receives-Orphan-Drug-Designation-for-Losmapimod-in-Facioscapulohumeral-Muscular-Dystrophy-FSHD-and-Announces-Expanded-Patent-Portfolio.html. Accessed Jan 29, 2020.
  • Rare Disease Database: Facioscapulohumeral Muscular Dystrophy. National Organization for Rare Disorders, rarediseases.org/rare-diseases/facioscapulohumeral-muscular-dystrophy/. Accessed Jan 29, 2020.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.